Autologous mononuclear cell (patient-derived)

Autologous mononuclear cells refer to the heterogeneous population of blood- or bone marrow-derived nucleated cells isolated from a patient's own body. These cells include lymphocytes, monocytes, hematopoietic stem and progenitor cells, endothelial progenitor cells, and small fractions of mesenchymal stromal cells[3][6]. They are not a single molecular target or receptor but are used experimentally or therapeutically in regenerative medicine and cell therapy for various diseases, most commonly for tissue repair following trauma, ischemia, or degenerative conditions. The mechanism of benefit is believed to involve paracrine signaling, promotion of angiogenesis, immune modulation, and potential differentiation into specialized cells. These therapies remain investigational or experimental for most indications. There is no canonical abbreviation, and as the term refers to a cell population collected for therapy rather than a defined molecule, it is not classified as a molecular therapeutic target. Use of this term as a "target" is incorrect and non-specific[2][3][6].

Other names

Autologous bone marrow mononuclear cell (BMMNC)Autologous peripheral blood mononuclear cell (PBMNC)Autologous mononuclear cells

Cell transplantation for tissue regeneration or modulation (paracrine signaling, differentiation, immune modulation, angiogenesis)[2][6] In immunotherapy, can be stimulated to become effector immune cells (e.g., for cancer)[7][8]